SEP 05, 2014 12:00 AM PDT

NSAIDs Stave Off Cancer Recurrence for Overweight Breast Cancer Patients, Study Finds

WRITTEN BY: Judy O'Rourke
Many adults may find popping a baby aspirin a day lessens the chance of a heart attack.

Researchers have now found that post-menopause, breast cancer patients who are overweight or obese, who incorporate hormone therapy into their treatment-and-who use nonsteroidal anti-inflammatory drugs (NSAIDs; eg, aspirin or ibuprofen) have a much lower rate of the cancer returning and a long interval should it return.

This subset of women has a relatively heightened risk of recurrence.

Their findings, published in the August 14 issue of Cancer Research, put forth a new option for lowering the incidence of breast cancer recurrence among this group of women.

Cancer researcher Linda deGraffenried, PhD, associate professor, School of Human Ecology, The University of Texas at Austin engineered the study in collaboration with Andrew Brenner, MD, an oncologist from the Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, and Murali Beeram, MD, a cancer specialist from the START Center for Cancer Care in San Antonio, Texas.

Employing a retrospective analysis of human subjects and cell cultures, the investigators found that NSAID use lowers the recurrence rate of the most common type of breast cancer-Er?-positive breast cancer--by 50 percent, and lengthens the duration of patients' disease-free interval by more than two years. ER-positive breast cancers, which multiply in response to exposure to the hormone estrogen, comprise about 75 percent of diagnoses.

The findings are preliminary, the researchers note, and further studies are being carried out to verify the results.

"Overweight or obese women diagnosed with breast cancer are facing a worse prognosis than normal-weight women," deGraffenried says. "We believe that obese women are facing a different disease. There are changes at the molecular level. We seek to modulate the disease promoting effects of obesity."

The researchers initially scoured medical records of 440 breast cancer patients, observing the prognoses of those who took NSAIDs versus those who did not.

The researchers created a second study to investigate how breast cancer cells act in the body. By immersing ER?-positive breast cancer cells in blood serum from obese women, they aimed to copy the conditions that encourage tumors to multiply, reproduce, and metastasize.

While the action that induces breast cancer in obese women to be more destructive and less receptive to treatment is not thoroughly understood, the researchers suggest that inflammation plays a key role. Their data also suggest inflammation negatively impacts the efficacy of aromatase inhibitors, a class of cancer drugs often prescribed to thwart cancer recurrence.

"Clinicians are finding that the five-year recurrence rate for postmenopausal women is much higher on aromatase inhibitors when the patient is obese," deGraffenried says. "We would like to identify which women are most likely to benefit from interventions like adding NSAIDs to treatment regimens."

Researcher Laura Bowers, The University of Texas at Austin, who oversaw the cell culture segment of the study, proposes that overweight or obese postmenopausal women - those at greater risk for breast cancer development - might profit from taking a low-dose aspirin daily. "What this study does is present great promise that a fairly inexpensive and nontoxic agent might benefit obese and overweight breast cancer patients who are at a higher risk of aromatase inhibitor failure - but further studies are needed to confirm these results," Bowers says.

An extended prospective study is on the drawing table to pinpoint disease biomarkers and keep track of patient response to the addition of NSAIDs to breast cancer treatment.
About the Author
  • Judy O'Rourke worked as a newspaper reporter before becoming chief editor of Clinical Lab Products magazine. As a freelance writer today, she is interested in finding the story behind the latest developments in medicine and science, and in learning what lies ahead.
You May Also Like
AUG 14, 2018
AUG 14, 2018
New Drug for Refractory Cutaneous T-cell Lymphoma
Mogamulizumab was approved by the FDA this month after a very successful Phase III clinical trial demonstrating its effectiveness in treating patients with challenging CTCL....
AUG 28, 2018
Drug Discovery
AUG 28, 2018
Combination Therapy for Advanced Melonoma
According to a research study led by UCLA, a bacteria-like agent used in combination with an immunotherapeutic drug may help patients survive longer with a...
OCT 02, 2018
Health & Medicine
OCT 02, 2018
Many Patients Are Unaware of Increased Cancer Risk
Just as recently as a few decades ago, many common health screenings were not readily available. Mammography, for breast cancer detection, wasn't ...
NOV 06, 2018
Genetics & Genomics
NOV 06, 2018
New Gene is Implicated in a Rare Cancer
Rodents are known as common research models, but zebrafish have been gaining ground as an attractive alternative for many reasons....
NOV 14, 2018
NOV 14, 2018
Reversing T Cell dysfunction in Cancer: Getting the Body to Fight its own Battles
Using the power of the immune system to eliminate cancerous cells has long the been the goal of immuno-oncology. Immune cells naturally recognize, destroy,...
JAN 01, 2019
JAN 01, 2019
Cancer patients have a higher risk of getting shingles
Shingles or herpes zoster is a viral infection that causes a painful rash; it is caused by the varicella-zoster virus the same virus that causes chickenpox...
Loading Comments...